| 产品目录 |
|
|
 |
|
|
 |
| Burkitts淋巴瘤细胞系 Daudi |
|
CCL-213 Burkitts淋巴瘤细胞系 Daudi
|
CCL-213™ |
|
|
|
Daudi |
|
G Klein |
|
IgM |
|
|
| Biosafety Level: |
2 |
|
frozen |
| Medium & Serum: |
See Propagation |
|
suspension |
|
Homo sapiens (human) |
|
lymphoblast
|
|
Organ: peripheral blood
Disease: Burkitt's lymphoma
Cell Type: B lymphoblast; |
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
|
| Related Cell Culture Products |
|
Isolation date: May, 1967 |
|
transfection host(Roche FuGENE® Transfection Reagents) |
|
complement, expressed
Fc, expressed |
|
Y |
|
negative |
|
D16S539: 10,12
D5S818: 8,13
D7S820: 8,10
THO1: 6,7
TPOX: 8,11
vWA: 15,17
Amelogenin: X,Y
CSF1PO: 12
D13S317: 11,12 |
|
Male human karyotype with stemline number of 46. The karyotype is diploid in 66% of the cells and is stable within the stemline. |
|
G6PD, B |
|
16 years |
|
male |
|
Black |
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Duration:
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C |
|
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 to 5 X 10(5) viable cells/ml.
Interval: Maintain cell density between 3 X 10(5) and 2 to 3 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020 |
|
22550: Ohsugi Y, et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J. Natl. Cancer Inst. 65: 715-718, 1980. PubMed: 6932523
23017: Klein E, et al. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 28: 1300-1310, 1968. PubMed: 4174339
26046: Huber C, et al. Surface receptors on human haematopoietic cell lines. Clin. Exp. Immunol. 25: 367-378, 1976. PubMed: 963908
26047: Nilsson K, et al. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int. J. Cancer 19: 337-344, 1977. PubMed: 14896
28315: Gao Y, et al. Induction of an exceptionally high-level, nontranslated, Epstein-Barr virus-encoded polyadenylated transcript in the uurkitts lymphoma line Daudi. J. Virol. 71: 84-94, 1997. PubMed: 8985326
32286: Cuthbert JA, Lipsky PE. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism. Cancer Res. 57: 3498-3504, 1997. PubMed: 9270019
32830: Yamaguchi Y, et al. Biochemical characterization and intracellular localization of the Menkes disease protein. Proc. Natl. Acad. Sci. USA 93: 14030-14035, 1996. PubMed: 8943055
33091: Lewis JA, et al. Inhibition of mitochondrial function by interferon. J. Biol. Chem. 271: 13184-13190, 1996. PubMed: 8662694
33115: Montoya JG, et al. Human CD4+ and CD8+ T lymphocytes are both cytotoxic to Toxoplasma gondii-infected cells. Infect. Immun. 64: 176-181, 1996. PubMed: 8557337 | |
![]() |
|
|
